Transcatheter Aortic Valve Replacement (TAVR)

TAVR treats a narrowed aortic valve, the one-way door between the heart's main pumping chamber and the body's largest artery. With age the valve can stiffen and clog with calcium so it no longer opens fully, a condition called aortic stenosis; the heart then has to push much harder, which over time causes breathlessness, chest tightness, dizziness and fainting. In TAVR the diseased valve is not removed. Instead a replacement valve, made of natural tissue mounted inside a small expandable frame, is delivered through a catheter and positioned precisely within the old valve. Once released it pushes the worn leaflets aside and starts directing blood flow immediately. Compared with traditional open surgery, where the chest is opened and the heart stopped, TAVR works through a small puncture or a short cut, so it suits patients for whom major surgery would carry higher risk.

TAVR is considered for severe aortic stenosis that is causing symptoms such as breathlessness on exertion, chest pressure, light-headedness or fainting, or that is beginning to strain the heart muscle. It was first offered to people at high or intermediate surgical risk, including older patients and those with other medical conditions that make open surgery more demanding, and experience with the technique continues to broaden. It is also used to replace a surgical tissue valve that has worn out years after an earlier operation, an approach known as valve-in-valve. A specialised heart team, bringing together cardiologists and cardiac surgeons, reviews each case and weighs TAVR against open valve surgery, because the best choice depends on age, anatomy, overall health and personal circumstances rather than on a single rule.

The procedure takes place in a hybrid operating theatre that combines advanced imaging with full surgical back-up. In most cases the new valve is introduced through the femoral artery in the groin, reached through a small puncture or short incision, so no chest opening is needed; when the groin vessels are unsuitable, the team can use another access point. Working under continuous X-ray and ultrasound guidance, the cardiologist threads the catheter up to the heart and positions the folded valve exactly inside the diseased one. The valve is then expanded, either by inflating a small balloon or by allowing a self-expanding frame to open, and immediately begins to control blood flow. The catheter is withdrawn and the access vessel closed. Many patients have the procedure under sedation with local anaesthesia and stay awake or lightly drowsy; others receive a light general anaesthetic. The whole procedure usually takes about one to two hours.

A good candidate has severe aortic stenosis confirmed by ultrasound of the heart, usually with symptoms, and has been assessed by a heart team as suited to the transcatheter approach. Preparation centres on detailed imaging: an echocardiogram measures the valve, and a CT scan maps the valve, the aorta and the access vessels so the right valve size and route are chosen precisely. Blood tests, an electrocardiogram and a review of kidney function and other conditions complete the work-up, and the coronary arteries are checked beforehand in case they also need attention. Blood-thinning medication is reviewed and adjusted on medical advice. For international patients, much of this planning can begin from home: recent scans and reports are reviewed remotely, the heart team confirms suitability, and the final imaging and checks are completed on arrival before the procedure is scheduled.

Recovery after TAVR is usually faster and gentler than after open-heart surgery because there is no breastbone to heal. Many patients are monitored briefly in a high-dependency area, then move to a normal ward, and are walking within a day. A short period of heart-rhythm monitoring is routine, and occasionally a small pacemaker is needed if the heart's electrical signal is affected. Most people go home after about two to four days and feel the benefit quickly, as breathlessness and tiredness ease once blood flows freely again. Planning a trip abroad, it is sensible to stay in the destination city for roughly one to two weeks so the team can confirm the valve is working well, the access site has healed and any medication is settled before you fly. Air travel is generally comfortable once that check is complete. Afterwards, follow-up continues remotely, and international patient teams commonly provide interpreters and coordinators so that language is never a barrier.

In experienced hands and a properly equipped hospital, TAVR is a well-established and safe procedure, though, like any heart intervention, it carries some risk. Possible issues include bleeding or bruising at the access site, changes in heart rhythm that may call for a pacemaker, a small leak around the new valve, stroke, or kidney strain from the imaging dye; the heart team takes careful steps to reduce each of these. The clear benefit is that severe aortic stenosis, which can be life-threatening when left untreated, is relieved without major surgery, so symptoms ease and daily life improves. Modern tissue valves are durable and designed to last many years. Choosing an experienced heart team, completing the imaging carefully and following the aftercare plan are the keys to a safe experience and a lasting result.